Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

CMM 520 Cancer > All things Breast + Gyn > Flashcards

All things Breast + Gyn Flashcards

1
Q

Modifiable Breast Cancer Risks

A

Alcohol use, weight, physical activity, radiation, occupational exposures, environment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Non-modifiable Breast Cancer Risks

A

Being a female, Aging, Ethnicity/Race, Hormones, Certain breast conditions (LCIS, atypical hyperplasia), DNA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Non-cancerous breast findings

A

Cysts, fibroadenomas, hyperplasia, papilloma, calcifications, radial scar, phyllodes tumor, lobular carcinoma in situ, atypical ductal hyperplasia, atypical lobular hyperplasia, flat epithelia atypia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Cancerous breast findings

A

ductal carcinoma in situ, invasive carcinoma (ductal, lobular, tubular, mutinous, medullary. Paget’s disease), phyllodes tumor,
inflammatory breast cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what can be both a non-cancerous and cancerous breast finding

A

phyllodes tumor
rare breast tumors that start in the connective (stromal) tissue of the breast, not the ducts or glands (which is where most breast cancers start). Most phyllodes tumors are benign and only a small number are malignant (cancer)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

NCCN breast screening guidelines for woman of average risk

A

annual mammogram at 40

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Treatments for breast cancer

A

surgery, chemo, radiation, hormonal therapy (tamoxifen), immunotherapy, PARP inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Modifiable cancer risks

A

obesity, medications, smoking, IUD, environment*

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

non-modifiable cancer risks

A

aging, being female, heredity, hormonal factors (early menarche, late menopause), chronic conditions, estrogen secreting tumor, infetitily

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Non-cancerous gynecologic findings

A

fibroid, polyps, cysts, endometrioma, cystadenoma, teratoma, germ cell tumors, sex cord stromal tumors, endometrial hyperplasia with atypia, endometrial intraepithelial neoplasia, borderline ovarian

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Cancerous gynecologic findings

A

epithelial carcinoma, endometrial cancer, germ cell tumors, sex cord stromal tumors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Ways to find gynecologic cancers

A

pelvic exam, pelvic or vaginal US, pelvic MRI, blood testing (CA-125), biopsy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

When is routine screening for ovarian cancer performed

A

if there is a strong family history

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

treatments for GYN cancers

A

surgery (i.e. TAH, BSO), chemo, radiation, progestin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

BRCA1 Cancer Risks

A

Breast (40-87)
Ovarian (16-59)
Prostate (16)
Pancreatic (1-3)
Male breast (1-2)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

BRCA2 Cancer Risks

A

breast (40-85)
prostate (27)
Ovarian (17-27)
Male breast (7-8)
Pancreatic (increased)
melanoma (increased)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

General NCCN testing guidelines

A

individuals with blood relative with known pathogenic variant
patients with limited prior testing and meeting other criteria
mutation identified in somatic tumor testing that has clinical implications
to aid in systemic therapy or surgical decision making
Ashkenazi Jewish ancestry

18
Q

Breast NCCN guidelines by age at dx and FHX

A

less than or equal to 45
46-50 with any unknown or limited FHX, multiple primary breast cancers, more than 1 close blood relative with breast, ovarian, pancreatic or prostate cancer at any age
greater or qual to 51: 1 or more close blood relative with breast cancer dx under 50, or male breast cancer at any age, ovarian cancer at any age, pancreatic cancer at any age, metic histology, 3 or more breast cancer dx in patient or close blood relatives, 2 or more close relatives with either breast or prostate cancer at any age
any age: to aid in systemic treatment for PARP inhibitors in metastatic setting; to aid in treatment of triple negative, lobular breast cancer with FHX of diffuse gastric cancer; male breast cancer

19
Q

NCCN Breast guidelines with only FHX

A

affected individual not meeting criteria, but with 1st or 2nd degree relative that does meet criteria
has greater than 5% probability using probability model

20
Q

Ovarian Cancer NCCN testing guidelines

A

General criteria; personal hx of epithelial ovarian cancer; family hx of 1st or 2nd deg relative with epithelial ovarian cancer at any age; unaffected but greater than 5% in probability model

21
Q

NCCN recommendations for BRCA 1 + 2 carriers BREAST

A

breast: monthly self breast exam, yearly clinical breast exams, mammograms, MRIs, chemoprevention, BL mastectomies
males: self breast exam, clinical breast exam, mammogram

22
Q

NCCN recommendations for BRCA 1 + 2 carriers OVARIES

A

bilateral saplingo-oophorectomy, TV ultrasound, CA-125 TESTING

23
Q

NCCN recommendations for BRCA 1 + 2 carriers PROSTATE

A

prostate specific antigen test, rectal exam

24
Q

BRCA 2 Melanoma recommendations

A

yearly full body skin + eye exams

25
AJ founder mutations
BRCA 1 187delAG, BRCA1 5385insC, BRCA2 617delT
26
BRCA2 Fanconi Anemia
AR; bone marrow failure, physical abnormalities, organ defects, increased risk for certain cancers; onset 6-8 years old; patients cannot undergo radiation
27
Genes associated with Hereditary Breast Cancer
BRCA1/2, PALB2, PTEN (Cowden), TP53 (Li-Fraumeni), CDH1(Hereditary Diffuse Gastric Cancer syndrome), STK11 (Puetz-Jeghers), ATM, CHEK2, NF1 (Neurofibromatosis type 1), MSH6 + PMS2 (Lynch), BARD1, BRIP1, RAD51 + RAD51...
28
ATM
AD, 17-33% increase chance of breast cancer, also associated to increase risk of ovarian, pancreatic and prostate cancer Ataxia Telangiectasiaa hereditary condition characterized by progressive neurologic problems that lead to difficulty walking and an increased risk of developing various types of cancer
29
BARD1
AD; 15-40% absolute risk; no other known cancer risks
30
BRIP1
AD; increased risk for breast and ovarian; counsel about Fanconi Anemia
31
CDH1
AD; Hereditary diffuse gastric cancer syndrome 39-52% breast cancer risk 33-83% gastric cancer risks prophylactic total gastrectomy is recommended between ages of 18 and 40; Under 18 is not recommended unless FHX of dx of gastric cancer before 25 upper endoscopy with multiple random biopsies every 6-12 months for should be offered to patients who elect to not pursue surgery, however may not adequately catch cancer
32
CHEK2
AD; 28-37% breast cancer risk, also increased risks for colon cancer; colonoscopy every 5 years at age 40 or 10 years prior to 1st degree relative dx
33
PALB2
AD; 33-58% breast cancer risks; risks for male breast cancer, pancreatic cancer, ovarian cancer, and prostate cancer
34
MSH6, PMS2
Lynch genes; AD increased risk for female breast, CRC, endometrial, ovarian, gastric, pancreas, bladder, biliary tract, urothelial, small bowel, prostate, Brian, CNS
35
NF1
Neurofibromatosis type 1; AD increase risk for breast cancer, brain tumors, leukemia, gastrointestinal stromal tumors, paragangliomas, and pheochrodmosytomas cafe au lait spots; inguinal or genital freckling, neurofibromas or gliomas, linch nodules, skeletal dysplasia, learning disabilities
36
PTEN
Cowden syndrome; AD Increased risks for breast, thyroid, kidney, uterine/endometiral, colorectal, melanoma Major criteria: breast cancer, endometrial cancer, follicular thyroid cancer, multiple GI hamartomas or ganglioneruomas, one biopsy proven trichelemmoma ... minor criteria: ASD, colon cancer, lipoma, thyroid structure lesions...
37
PTEN Management
annual comprehensive physical exams (including skin & thyroid), clinical breast exam yearly start at 25 or 5-10 years before earliest dx colposcopy and endometrial screenings at 35 renal US at 45
38
RAD51C, RAD51D
AD; Risks for breast and ovarian cancer counsel about Fanconi Anemia
39
STK11
Peutz-Jeghers Syndrome; AD Increased risks for: breast: CRC, pancreatic, stomach, ovarian, lung, small intestine, cervical, uterine, testicular
40
TP53/ P53
BONES, BRAIN, BLOOD, BREAST Li-Fraumeni; AD increased risks for breast, CRC, endometrial, gastric, melanoma, ovarian, pancreatic, prostate, brain, sarcoma, leukemia, lymphoma
41
Classic Li-Fraumeni Criteria
Combo of pt dx with sarcoma under 45 and a 1st degree relative diagnosed with cancer under 45 and additional 1st or 2nd degree family member of same lineage dx with cancer under 45 or sarcoma at any age
42
Chompet Li-Fraumeni Criteria
Pt with tumor from LFS tumor spectrum (soft tissue sarcoma, osteosarcoma, CNS tumor, breast cancer, adrenocortical carcinoma) before 46 AND at least one 1st or 2nd relative with any of the mentioned cancers before 56 or multiple primaires at any age OR PT with multiple tumors (not breast tumors); two of which are LFS tumors w/ initial cancer before 45 OR PT with adrenocortical carcinoma, or choroid plexus carcinoma or rhabdomyosarcoma, of embryonal analplastic subtype OR breast cancer before 31

CMM 520 Cancer (16 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions